Location · Washington D.C., DC
Clinical trials in Washington D.C., DC
221 recruiting studies have a site in Washington D.C., and 73 of them accept healthy volunteers.
221 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Priovant Therapeutics, Inc.
- Location
- Washington D.C., DC + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Washington D.C., DC + 58 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
- Location
- Washington D.C., DC + 40 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Sanofi
- Location
- Washington D.C., DC + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
Kiniksa Pharmaceuticals International, plc
- Location
- Washington D.C., DC + 20 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 2/Phase 3
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Kiniksa Pharmaceuticals International, plc
- Location
- Washington D.C., DC + 29 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Annexon, Inc.
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 8–85
- RecruitingPhase 3
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
SymBio Pharmaceuticals
- Location
- Washington D.C., DC + 24 other US sites
- Eligibility basics
- Ages 2 mo+
- RecruitingPhase 3
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
Biohaven Therapeutics Ltd.
- Location
- Washington D.C., DC + 52 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Washington D.C., DC + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
- Location
- Washington D.C., DC + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Ambros Therapeutics, Inc.
- Location
- Washington D.C., DC + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi
- Location
- Washington D.C., DC + 17 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Washington D.C., DC + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 16 other US sites
- Eligibility basics
- Ages 12–100
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Washington D.C., DC + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Pfizer
- Location
- Washington D.C., DC + 76 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sanofi
- Location
- Washington D.C., DC + 20 other US sites
- Eligibility basics
- Ages 10–65
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Washington D.C., DC + 18 other US sites
- Eligibility basics
- Ages 6–14
- Recruiting
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device…
Shockwave Medical, Inc.
- Location
- Washington D.C., DC + 16 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
Artivion Inc.
- Location
- Washington D.C., DC + 21 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
DiscGenics, Inc.
- Location
- Washington D.C., DC + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Washington D.C., DC + 28 other US sites
- Eligibility basics
- Ages 6–17